Statistics for Quince Therapeutics, (id:8405 QNCX)
Valuation metrics
Market cap
73.57M
Enterprise value
28.51M
Trailing P/E (ttm)
-2.33
Forward P/E
-5.48
PEG ratio
-5.48
Price/Sales (ttm)
Price/Book (mrq)
1.57
Enterprise Value/Revenue
Enterprise Value/EBITDA
-0.98
Overview
Shares outstanding
43.28M
Float
34.60M
Shares short
1.91M
% Held by insiders
0.14%
% Held by institutions
0.25%
Average volume (10 days)
1.77M
Average volume (90 days)
Price summary
52-Week low
0.51
52-Week high
2.45
52-Week change
52.55%
Beta
0.71
50-Day moving average
0.91
200-Day moving average
0.93
Dividends and splits
Forward annual dividend rate
Forward annual dividend yield
Trailing annual dividend rate
0.00%
Trailing annual dividend yield
0.00
5-Year annual dividend yield
Payout ratio
0.00
Dividend date
Ex-dividend date
Last split factor
2:1
Last split date
Financials
Fiscal yearFiscal year ends
December 31th, 2023
Most recent quarter (mrq)
June 30th, 2024
Profitability
Profit margin
0.00%
Operating margin
0.00%
Operational effectiveness
Return on assets
-16.50%
Return on equity
-79.38%
Income statement
Revenue (ttm)
0.00
Revenue per share (ttm)
0.00
Quarterly revenue growth (yoy)
Gross profit (ttm)
0.00
EBITDA
-29,129,000.00
Net income to common (ttm)
-53,123,000.00
Diluted EPS (ttm)
-1.26
Quarterly earnings growth (yoy)
Balance sheet
Total cash (mrq)
59.44M
Total cash per share (mrq)
1.37
Total debt (mrq)
14.38M
Total Debt/Equity (mrq)
30.62
Current ratio (mrq)
614.60%
Book value per share (mrq)
1.08
Cash flow
Cash flow statement
-27,988,000.00
Levered free cash flow (LFCF)
-7,836,125.00